Microcap Ledger Foghorn Therapeutics Inc. $FHTX
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Global Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Cambridge, MA
- Fiscal year end
- December 31
- Shares outstanding
- 59,385,315 [10-Q 2026-08-06]
What the company doesAI summary of filing
Foghorn Therapeutics is a clinical-stage biotechnology company developing small-molecule medicines that target the chromatin regulatory system to treat serious diseases, primarily oncology. The company's proprietary Gene Traffic Control platform enables identification and validation of genetic dependencies within the chromatin regulatory system, which it says is implicated in approximately 50 percent of all cancers. Foghorn is currently developing more than seven programs across multiple targets including SMARCA2, CBP, EP300, and ARID1B, with its most advanced candidate, FHD-909 (a selective SMARCA2 inhibitor), now in Phase 1 clinical trials under a collaboration with Eli Lilly. The company is pre-revenue and generates income through its strategic collaboration agreement with Lilly, which included an upfront payment of $300 million and an $80 million equity investment, with additional milestone payments and royalties on future product sales. [10-K 2026-03-11]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $19.34M | −$27.07M | −$43.11M | $68.08M | [10-Q 2026-08-06] |
| FY ended Dec 2025 | $30.91M | −$74.28M | −$86.10M | $80.88M | [10-K 2026-03-11] |
| FY ended Dec 2024 | $22.60M | −$86.62M | −$100.41M | $55.45M | [10-K 2026-03-11] |
- Quarterly cash burn
- −$21.55M
- Cash runway Estimate
- ~9.5 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-10-28 | 55,593,131 | [10-Q 2024-11-04] |
| 2025-02-28 | 55,612,239 | [10-K 2025-03-06] |
| 2025-05-06 | 55,741,373 | [10-Q 2025-05-14] |
| 2025-07-28 | 56,529,969 | [10-Q 2025-08-05] |
| 2025-10-31 | 56,551,289 | [10-Q 2025-11-05] |
| 2026-02-27 | 58,700,246 | [10-K 2026-03-11] |
| 2026-04-30 | 58,713,922 | [10-Q 2026-05-07] |
| 2026-07-31 | 59,385,315 | [10-Q 2026-08-06] |
- Shelf registration
- S-3 filed 2025-01-24; declared effective 2025-01-31 [S-3 2025-01-24]
Listing status
Current status: 1 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2025-01-24. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2025-01-24 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-01-24] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-10-05 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-10-01 | 8-K | Exit or disposal costs; Regulation FD disclosure |
| 2026-08-06 | 10-Q | Quarterly report |
| 2026-08-06 | 8-K | Results of operations; Regulation FD disclosure |
| 2026-06-24 | 8-K | Shareholder vote results |
| 2026-05-15 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-05-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-05-07 | 10-Q | Quarterly report |
| 2026-05-07 | 8-K | Results of operations; Regulation FD disclosure |
| 2026-05-06 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-04-30 | DEF 14A | Proxy statement |
| 2026-04-21 | 8-K | Regulation FD disclosure; Other events |
Alerts for $FHTX
Email me when Foghorn Therapeutics Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.